- CEPI, the Coalition for Epidemic Preparedness Innovations (CEPI), Translational Health Science and Technology Institute (THSTI ) and Panacea Biotec to develop vaccine candidates that could provide broad protection against SARS-COV-2 variants and other Betacoronaviruses.
- CEPI will provide funding of up to 12.5m dollars to support the development of multi-epitope, nano particle based vaccine candidates and advance the manufacturing process.
- THSTI and Panacea Biotec will design and select the lead antigen through proof-of-concept preclinical studies, and undertake initial clinical development through Phase I/II studies
Panacea Biotec to develop Betacoronavirus vaccines in partnership with CEPI & THSTI
Related Posts
Leave a Reply
Recent News
